Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced.

Slides:

Advertisements

Similar presentations

1 Sitemap Storyflow Title slideOverview slide13.6 months PFSSymptom controlQoL OS across 7 trials3 months OS > 12 month OS Summary slide.

Advertisements

CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.

Early Treatment of Relapsed Ovarian Cancer Based on CA125 Level Alone Versus Delayed Treatment Based on Conventional Clinical Indicators Results of the.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

1 LUX-Lung 3 clinical trial ECOG=Eastern Cooperative Oncology Group. Sequist LV et al. J Clin Oncol. 2013;31(27): Treatment-naïve Advanced NSCLC.

Volume 389, Issue 10072, Pages (March 2017)

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

LUX-Lung 6 clinical trial

LUX-Lung 3 clinical trial

Volume 112, Pages (October 2017)

Volume 18, Issue 6, Pages e1 (November 2017)

ABI-007-NSCL-003 ABOUND.sqm: Interim Results of nab®-Paclitaxel + Carboplatin Induction Therapy in Patients With Squamous Non-Small Cell Lung Cancer Interim.

Long-Term Health-Related Quality of Life in Patients With Rectal Cancer After Preoperative Short-Course and Long-Course (Chemo) Radiotherapy Lisette.

Managing Metastatic Bone Pain: The Role of Bisphosphonates

LUX-Lung 8 A randomised, open-label phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower- Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Volume 151, Issue 1, Pages (January 2017)

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Evaluating Cognitive, Emotional, and Physical Fatigue Domains in Daily Practice by Single-Item Questions in Patients With Advanced Cancer: A Cross-Sectional.

Volume 152, Issue 6, Pages (December 2017)

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France Nicolas Despiégel, Chantal Touboul, Alain.

Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced.

Jean Claude Dusingize, Catherine M. Olsen, Nirmala P

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain.

Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based.

Type D Personality in Gastric Cancer Survivors: Association With Poor Quality of Life, Overall Survival, and Mental Health Jia-kui Zhang, MD, Li-li Fang,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based.

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,

Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.

Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial)

Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated.

Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment according to (A) the QLQ-C30 and (B) the QLQ-LC13.

The Impact of Symptoms, Coping Capacity, and Social Support on Quality of Life Experience Over Time in Patients with Lung Cancer Ingela Henoch, RN, PhD,

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.

Volume 17, Issue 8, Pages (August 2016)

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Cancer Stem Cells in Squamous Cell Carcinoma

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination.

Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and.

Association Between Symptom Distress and Survival in Outpatients Seen in a Palliative Care Cancer Center J. Lynn Palmer, PhD, Michael J. Fisch, MD, MPH

Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Physiologic vs Chronologic Age

Thoracic Surgery Survey on Lung Cancer Management

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Afatinib versus erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung: a subgroup analysis of the Phase.

Physiologic vs Chronologic Age

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based.

Clinically meaningful worsening (versus improvement or no change)

Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus.

Presentation transcript:

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy Enriqueta Felip, Vera Hirsh, Sanjay Popat, Manuel Cobo, Andrea Fülöp, Charles Dayen, José M. Trigo, Richard Gregg, Cornelius F. Waller, Jean-Charles Soria, Glenwood D. Goss, James Gordon, Bushi Wang, Michael Palmer, Eva Ehrnrooth, Shirish M. Gadgeel Clinical Lung Cancer DOI: 10.1016/j.cllc.2017.06.002 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Questionnaire Completion Ratea aOn the basis of completion of any item in the questionnaire. Cycle 1 is the baseline assessment since questionnaires were completed by patients before seeing the investigator and before any clinical assessment/treatment. Clinical Lung Cancer DOI: (10.1016/j.cllc.2017.06.002) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Proportion of Patients With Improvements in Symptoms Abbreviations: GHS = global health status; OR = odds ratio (afatinib vs. erlotinib); QoL = quality of life. Clinical Lung Cancer DOI: (10.1016/j.cllc.2017.06.002) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Time to Deterioration of (A) Dyspnea, (B) Cough, (C) Pain Abbreviation: HR = hazard ratio. Clinical Lung Cancer DOI: (10.1016/j.cllc.2017.06.002) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Time to Deterioration of Symptoms Abbreviations: GHS = global health status; HR = hazard ratio; Q = question; QLQ-C30 = Quality of Life Questionnaire C30; QLQ-LC13 = Quality of Life Questionnaire Lung Cancer-13; QoL = quality of life. Clinical Lung Cancer DOI: (10.1016/j.cllc.2017.06.002) Copyright © 2017 The Authors Terms and Conditions

Figure 5 Difference in Mean Scores Over Time for Cough, Dyspnea and Pain (A) and GHS and Functional Scales (B) Abbreviations: GHS = global health status; Q = question; QLQ-C30 = Quality of Life Questionnaire C30; QLQ-LC13 = Quality of Life Questionnaire Lung Cancer-13; QoL = quality of life. Clinical Lung Cancer DOI: (10.1016/j.cllc.2017.06.002) Copyright © 2017 The Authors Terms and Conditions

Supplemental Figure 1 Differences in Mean Scores for (A) Coughing, (B) Dyspnea, and (C) GHS/QoL in the Primary Analysis and Using Additional Data Cutoffs and Truncation Points Abbreviations: GHS = global health status; QoL = quality of life. Clinical Lung Cancer DOI: (10.1016/j.cllc.2017.06.002) Copyright © 2017 The Authors Terms and Conditions

Supplemental Figure 2 Time to Deterioration in Individual Items of (A) QLQ-C30 and (B) QLQ-LC13 Abbreviations: HR = hazard ratio; Q = question; QLQ-C30 = Quality of Life Questionnaire C30; QLQ-LC13 = Quality of Life Questionnaire Lung Cancer-13; QoL = quality of life. Clinical Lung Cancer DOI: (10.1016/j.cllc.2017.06.002) Copyright © 2017 The Authors Terms and Conditions

Supplemental Figure 3 Difference in Mean Scores Over Time in Individual Items of (A) QLQ-C30 and (B) QLQ-LC13 Abbreviations: HR = hazard ratio; Q = question; QLQ-C30 = Quality of Life Questionnaire C30; QLQ-LC13 = Quality of Life Questionnaire Lung Cancer-13. Clinical Lung Cancer DOI: (10.1016/j.cllc.2017.06.002) Copyright © 2017 The Authors Terms and Conditions